Should all adjuvant breast cancer patients receive a bisphosphonate?

AUTOR(ES)

Cameron, David A

FONTE

BioMed Central

RESUMO

This commentary discusses the report by Trevor Powles and colleagues on their double-blind, placebo-controlled randomised trial of 2 years' adjuvant oral clodronate. Although the reported survival benefit in the clodronate-treated group confirms the results of one prior study as well as the generally held view that bisphosphonates could be advantageous, the reviewer does not feel that the data support the universal use of this additional adjuvant therapy.

Documentos Relacionados

• Should All Patients with Risk Factors for Ischemic Heart Disease Receive Aspirin?
• Websites on screening for breast cancer: Not all advocacy groups receive industry funding
• Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial
• Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study
• Hypocalcaemia after intravenous bisphosphonate: Adjuvant bisphosphonate is not currently accepted practice